A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Nivolumab (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2017 Planned End Date changed from 31 Dec 2019 to 9 Aug 2019.